In its 10-Q quarterly earnings report filed with the SEC on August 14, InforMax warned that it has been notified by Nasdaq that it is not in compliance with the $1.00 minimum bid listing requirement for continued listing on the Nasdaq National Market.

As a result, InforMax has until October 29, 2002, to demonstrate a closing bid price of at least $1.00 per share or more for a minimum of ten consecutive trading days. If the company fails to do so, it risks delisting.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.